Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2017 · 10-Q
Revenue$2.64M$2.64M−78.9% vs Q3 2016 Net Income-$34.13M-$34.13MN/M vs Q3 2016 EPS Diluted-$0.40-$0.40N/M vs Q3 2016 Operating Income-$29,185,471N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,901,232N/M Margins · derivedOperating margin-1103.6%−942.6 pt vs Q3 2016
Net margin-1290.8%−1125.2 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 8, 2017 · 39 d after period end